Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on May 7, 2020, detailing key outcomes from its Annual Meeting of Stockholders held on May 6, 2020. The most significant event for investors is the approval of an amendment to increase the number of authorized common shares to facilitate a three-for-one stock split. This move, effective immediately upon filing with Delaware, aims to make the stock more accessible to a wider range of investors and potentially increase liquidity. Additionally, the filing confirms the election of all director nominees, the approval of executive compensation and the 2020 Nonemployee Directors Stock Incentive Program, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. The company also announced the retirement of a board member and the appointment of a new Lead Independent Director, alongside the previously mentioned stock split, through an accompanying press release.
Key Highlights
- 1Stockholders approved an amendment to increase authorized common stock from 350 million to 1.05 billion shares.
- 2The increase in authorized shares is to effect a three-for-one forward stock split, making the stock more accessible.
- 3All director nominees were elected to serve until the next annual meeting.
- 4The advisory proposal on executive compensation was approved.
- 5The 2020 Nonemployee Directors Stock Incentive Program was approved.
- 6PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2020.
- 7Wesley von Schack retired from the Board of Directors, and Martha Marsh was appointed Lead Independent Director.